Abbott Laboratories (ABT) said Sunday its investigational, leadless Aveir Conduction System Pacing device showed safety and performance in a clinical feasibility study.
The device delivers conduction pacing to the heart's left bundle branch area by mimicking the heart's electrical rhythm, the company said.
Abbott also recently started enrolling patients in a clinical trial of up to 414 people to evaluate the safety and effectiveness of its investigational CSP Implantable Cardioverter-Defibrillator lead.
The US Food and Drug Administration recently granted breakthrough device designations to both the Aveir and CSP devices, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。